In conclusion, our insights into the mechanisms underpinning E-cadherin synthetic lethality obtained in both in vitro models and whole gastric tumours provide a framework for the rational selection of drugs that could be used to selectively target E-cadherin-deficient cancers. This evidence concerns the gene CDH1 and cancer.